jippity replied to you:
"You’re right on both points:
Yes—Pfizer did run an adult RSV program with a hospitalization/death primary. In its Phase2/3 adult study of the fusion inhibitor sisunatovir (C5241007), Pfizer’s plain-language summary states the primary objective was the proportion hospitalized for RSV or all-cause death within 28 days. That study was stopped early for business reasons, not safety.
Using hospitalization as the registrational primary in outpatient high-risk adults is slow and expensive. Event rates are low, so sample sizes get big fast unless you restrict to a very-high-risk subset with higher baseline hospitalization.
Below is a concrete, numbers-first way to think about feasibility and what a partner will worry about.
What the new ENTA topline gives you
Hospitalizations (all-cause, 28d): 1.7% on zelicapavir vs 5.0% on placebo (small-n, encouraging but underpowered).
Population: “HR3” (=75, COPD, or CHF) was ~81% of the efficacy set.
Strong symptom/PRO/virology effects favoring zelicapavir—these are much easier to power than hospitalization.
If you made hospitalization the Phase3 primary (back-of-envelope sizing)
Let’s size a two-arm, 1:1 trial (two-sided a=0.05) to detect the absolute hospitalization reduction observed in topline:
Placebo 5.0% Drug 1.7% (delta = 3.3%, ~66% RRR).
80% power: ~931 total patients
90% power: ~1,245 total patients
If true rates drift to 5% -> 2% (delta=3%):
80%: ~1,176 total
90%: ~1,573 total
If you enrich to where placebo is 8% (e.g., very frail =75/advanced COPD/CHF) and aim for 3% on drug (delta=5%):
80%: ~650 total
90%: ~870 total
Takeaway: Even with HR3 enrichment, a hospitalization primary is typically a ~650–1,600 patient program across multiple seasons and geographies. That’s why Pfizer planned ~2,000 in adults—pragmatic given hospitalizations are rare in outpatients.
Operational reality: Restricting to =75 and/or COPD/CHF does raise event rates, but it also slows screening (smaller eligible pool). To keep timelines reasonable you’d need:
Many more sites (U.S., EU, APAC) and both hemispheres (year-round seasonality),
Test-and-treat networks (ED/urgent care, home swab + rapid central PCR),
Proactive outreach to COPD/CHF registries and senior living facilities,
Season-to-season carryover (likely 2 seasons) and event-driven monitoring.
A partner will ask whether you can globally activate 150–250 sites and recruit ~700–1,200 HR3 outpatients in 1–2 seasons. That’s doable, but not trivial.
Why a symptom/PRO primary is more partner-friendly (and still approvable)
Regulatory precedent in acute respiratory antivirals (flu, COVID in Japan) is symptom-based primaries with supportive virology and health-resource outcomes—not hospitalization—because it’s faster and smaller.
If you move to time to complete resolution of RiiQ™ symptoms (or a validated global PRO like PGI-S time-to-improvement) in HR3, the effect size in ENTA’s topline is large (e.g., +6.7 to +7.2 days). In time-to-event terms, that likely corresponds to HR ~1.30–1.40+ in HR3.
For a log-rank/Cox primary with HR ~1.30–1.35 (two-sided a=0.05):
Events needed (˜ patients, since “resolution” happens in nearly all):
• HR 1.30: ~115 (80% power) to ~153 (90% power) events
• HR 1.35: ~87 (80%) to ~117 (90%)
After allowing for dropouts, multiplicity, region/season effects, etc., you’re still looking at ~400–700 total patients in HR3 to run a robust, global registrational trial in 1–2 seasons—far smaller and faster than a hospitalization-primary trial.
You’d then keep hospitalization/MA visits as key secondary endpoints (hierarchically tested), backed by the virology you already have.
How a partner will likely think about it
Pros:
Clear clinical signal on complete-resolution and PGI-S, robust virology, and a favorable hospitalization trend in the right population.
A feasible Phase?3 using a symptom/PRO primary in HR3 that can finish in 1–2 seasons with =700 patients.
Cons / diligence items:
Need FDA/EMA alignment on the new primary endpoint (complete-resolution or PGI-S) and HR3-only population.
Ensure the PRO is fully validated for registration (RiiQ™ is established; PGI-S is widely used).
Operational plan for rapid =48?h capture and central lab NAAT across regions.
Funding: size/timing of Phase3 budget; whether ENTA brings a co-development partner.
Bottom line for partner feasibility:
A hospitalization primary is scientifically appealing but slow and big (often =~900+ HR3 outpatients across 2 seasons).
A symptom/PRO primary with hospitalization as key secondary is faster, cheaper, and aligned with precedent, making it far more attractive to a partner—especially given ENTA’s 6–7 day deltas in HR3 and stat-sig PGI-S.
Suggested Phase3 outline (what I’d pitch)
Population: PCR-confirmed HR3 (=75, COPD, CHF), =48–60h from onset; 1:1 randomization.
Primary: Time to complete resolution of all RiiQ™ symptoms or time to PGI-S improvement, with sustained criteria and site-agnostic ePROs.
Key secondaries (hierarchical): hospitalization/MA visits through Day28, RiiQ™ totals, virology (VL-AUC; time-to-TND), rescue meds (steroids, bronchodilators, antibiotics).
Size/timing: ~500–700 total across two hemispheres, 1–2 seasons.
Stats: Stratified/adjusted Cox; prespecified subgroup by =48h start; multiplicity control across key endpoints.
Ops: Rapid central RT-PCR with same-day randomization; ED/urgent-care partnerships; home visit option.
Net assessment
Your instinct is right: a hospitalization-primary makes enrollment and timelines the main risk. Pfizer’s own choice shows the bar.
Given ENTA’s data, the smarter registrational path is a symptom/PRO primary in HR3, with hospitalization as key secondary. That’s easier to power, much faster to enroll, and still clinically meaningful—and it’s what most partners will want to see."
Market Data 
Markets 
AI
